In vivo validation of sortilin-targeting drug candidates in a clinically relevant glioblastoma tumour model at the Centre for Preclinical Cancer Treatment (PCT), Uppsala University
| Reference number | |
| Coordinator | Sortina pharma AB |
| Funding from Vinnova | SEK 542 400 |
| Project duration | November 2026 - March 2028 |
| Status | Ongoing |
| Venture | Research infrastructure - utilisation and collaboration |
| Call | Support to small and medium-sized companies for the use of life science infrastructure |
Purpose and goal
The aim is to investigate, at the Centre for Preclinical Cancer Treatment (PCT), Uppsala University, whether Sortina’s two lead sortilin inhibitors are effective against glioblastoma in a clinically relevant intracranial model. The objective is to establish the model and dosing, evaluate efficacy as monotherapy and in combination with temozolomide, and generate a decision basis for selecting a candidate molecule ahead of GLP toxicology, CMC and CTA/IND.
Expected effects and result
The project is expected to provide data on dosage and efficacy in a clinically relevant intracranial model, as monotherapy and in combination with temozolomide. The results provide a basis for candidate molecule selection and for continued development towards GLP toxicology, CMC and CTA/IND. In the longer term, the project may contribute to a new treatment option for glioblastoma, strengthen Sortina´s funding opportunities and deepen national collaboration in CNS oncology.
Planned approach and implementation
The project will be carried out in five work packages over 17 months, with the Centre for Preclinical Cancer Treatment (PCT) as the performing partner and Sortina leading the project. The model, protocol and dosing will be established first. Efficacy will then be evaluated in intracranial studies, concluding with a compilation of the results into a decision basis for further development.